With decades of combined experience in biologics development and translational medicine, our scientists have pioneered the Antibody Lock Technology. This groundbreaking platform enables conditionally active antibodies to target disease sites with unprecedented accuracy. From early-stage discovery to advanced preclinical validation, our team integrates molecular design, protein engineering, and pharmacological insight to accelerate the development of next-generation biologics.